Becton Dickinson Price to Free Cash Flow Ratio 2010-2022 | BDX

Historical price to free cash flow ratio values for Becton Dickinson (BDX) since 2010. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Becton Dickinson Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2022-07-06 246.28 37.47
2022-03-31 258.54 $6.57 39.34
2021-12-31 243.62 $9.00 27.07
2021-09-30 237.30 $11.70 20.29
2021-06-30 234.02 $14.58 16.05
2021-03-31 233.17 $14.32 16.28
2020-12-31 239.13 $12.09 19.78
2020-09-30 221.61 $9.66 22.93
2020-06-30 227.12 $8.80 25.80
2020-03-31 217.40 $9.08 23.93
2019-12-31 256.45 $10.32 24.86
2019-09-30 237.80 $8.64 27.54
2019-06-30 236.21 $8.86 26.67
2019-03-31 233.32 $7.57 30.83
2018-12-31 209.86 $7.11 29.51
2018-09-30 242.29 $7.44 32.55
2018-06-30 221.74 $7.36 30.11
2018-03-31 199.93 $6.97 28.68
2017-12-31 196.83 $7.84 25.11
2017-09-30 179.56 $8.15 22.02
2017-06-30 178.14 $6.25 28.52
2017-03-31 166.85 $8.58 19.44
2016-12-31 149.98 $7.99 18.77
2016-09-30 162.11 $8.58 18.90
2016-06-30 152.40 $9.16 16.64
2016-03-31 135.90 $7.76 17.52
2015-12-31 137.31 $6.11 22.46
2015-09-30 117.71 $5.46 21.54
2015-06-30 125.13 $4.30 29.08
2015-03-31 126.31 $4.11 30.77
2014-12-31 121.90 $5.21 23.42
2014-09-30 99.27 $5.53 17.96
2014-06-30 102.71 $6.84 15.01
2014-03-31 101.18 $6.73 15.03
2013-12-31 95.04 $6.21 15.31
2013-09-30 85.60 $5.67 15.10
2013-06-30 84.16 $4.72 17.84
2013-03-31 81.01 $5.45 14.87
2012-12-31 65.88 $5.27 12.51
2012-09-30 65.77 $5.45 12.07
2012-06-30 62.21 $5.03 12.37
2012-03-31 64.23 $4.05 15.85
2011-12-31 61.44 $3.83 16.03
2011-09-30 59.91 $4.59 13.05
2011-06-30 70.06 $4.35 16.12
2011-03-31 64.42 $4.59 14.02
2010-12-31 68.03 $4.63 14.69
2010-09-30 59.35 $4.00 14.83
2010-06-30 53.87 $4.39 12.28
2010-03-31 62.39 $4.43 14.09
2009-12-31 62.20 $4.87 12.77
Sector Industry Market Cap Revenue
Medical Medical & Dental Supplies $70.676B $20.248B
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
Stock Name Country Market Cap PE Ratio
McKesson (MCK) United States $46.288B 13.61
AmerisourceBergen (ABC) United States $29.474B 13.60
West Pharmaceutical Services (WST) United States $22.672B 34.54
Laboratory Of America Holdings (LH) United States $22.247B 9.29
Cooper (COO) United States $15.585B 23.99
Cardinal Health (CAH) United States $14.234B 10.93
CONMED (CNMD) United States $2.863B 29.57
Invacare (IVC) United States $0.048B 0.00